Funding for this research was provided by:
Laura and John Arnold Foundation (NA)
Conseil des Arts du Canada (NA)
BlueCross BlueShield of South Carolina Foundation (NA)
Children’s Trust of South Carolina (NA)
Health Care Delivery Initiative (NA)
Received: 27 April 2020
Accepted: 18 November 2020
First Online: 4 December 2020
Ethics approval and consent to participate
: All participants in the study will provide documented informed consent. The study was approved by the Harvard T.H. Chan School of Public Health Institutional Review Board (IRB15-2939). Permissions were also obtained from cooperating institutions. The following IRBs have approved Harvard’s oversight of this research study: Massachusetts Institute of Technology, South Carolina Department of Health and Environmental Control (DHEC), IRB00000092 (which includes DHEC agencies covering the Upstate, Pee Dee, Lowcountry and Midlands regions), McLeod Health System, IRB00004313, Greenville Health System, and Spartanburg Regional Health System, IRB00001369.
: Our manuscript does not include any individual person’s data in any form.
: KB currently serves on the Board of directors of Eli Lilly and HMS and on advisory panels for the Congressional Budget Office and National Institute for Health Care Management. KB is also a Trustee of the Mayo Clinic, the Chicago Council on Global Affairs, and NORC at the University of Chicago. None of the above is expected to profit as a result of the publication of this manuscript. The other authors have no competing interests to declare.